Home › Neuroblastoma › New York
Neuroblastoma clinical trials in New York
13 studies for Neuroblastoma are looking for participants at sites in New York.
Cities in New York
Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
- Memorial Sloan Kettering Cancer Center, New York
RecruitingObservational study
All ages · All sexes · Updated Oct 5, 2026 · NCT00588068Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Albany Medical Center, Albany
- Roswell Park Cancer Institute, Buffalo
- NYU Langone Hospital - Long Island, Mineola
- and 7 more
RecruitingPhase 3
Up to age 30 · All sexes · Updated Oct 2, 2026 · NCT06172296A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 2Healthy volunteers welcome
All ages · All sexes · Updated Sep 30, 2026 · NCT04936529Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Memorial Sloan Kettering Cancer Center ( Site 1010), New York
- New York Medical College ( Site 1023), Valhalla
RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Sep 17, 2026 · NCT06395103N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 2
18 Months – 19 Years · All sexes · Updated Aug 28, 2026 · NCT06528496Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Albany Medical Center, Albany
- Maimonides Medical Center, Brooklyn
- Roswell Park Cancer Institute, Buffalo
- and 8 more
RecruitingPhase 3
365 Days – 30 Years · All sexes · Updated Aug 25, 2026 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119SPEARHEAD-3 Pediatric Study
- Memorial Sloan Kettering Kids, New York
RecruitingPhase 1/2
Ages 2 to 21 · All sexes · Updated Aug 11, 2026 · NCT05642455A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
- Memorial Sloan Kettering Suffolk-Commack (Consent only), Commack
- Memorial Sloan Kettering Westchester (Consent only), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
RecruitingPhase 2
All ages · All sexes · Updated Jul 28, 2026 · NCT06057948Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 2
Ages 1 and older · All sexes · Updated May 29, 2026 · NCT00107289Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
- New York Medical College, Valhalla
RecruitingPhase 1
Ages 1 to 30 · All sexes · Updated Apr 15, 2026 · NCT04308330Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
- Albert Einstein College of Medicine, Children's Hospital at Montefiore, The Bronx
- New York Medical Center/ Maria Fareri Children's Hospital, Valhalla
RecruitingPhase 2
Ages 1 to 50 · All sexes · Updated Mar 13, 2026 · NCT01804634A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
- Children's Hospital at Montefiore, The Bronx
RecruitingPhase 2
18 Months – 40 Years · All sexes · Updated Aug 12, 2025 · NCT05135975From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.